SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 26, 2004
United Therapeutics Corporation
_______________________________________
(Exact Name of Registrant as Specified in Charter)
| Delaware | 000-26301 | 52-1984749 | ||
|
|
||||
| (State or Other | (Commission | (I.R.S. Employer | ||
| Jurisdiction of | File Number) | Identification Number) | ||
| Incorporation) |
| 1110 Spring Street | ||
| Silver Spring, MD | 20910 | |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(301) 608-9292
———————————————
Item 5. Other Events.
On January 26, 2004, United Therapeutics Corporation issued a press release announcing (i) the bioequivalence of Remodulin when delivered intravenously as compared to subcutaneous delivery, and (ii) no net patient growth in the fourth quarter of 2003 due to higher patient discontinuations and the year-end holiday slow down in new patient starts.
Item 7. Exhibits
(c) Exhibits
| Exhibit No. | Description of Exhibit | |
| 99 | Press release dated January 26, 2004 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| UNITED THERAPEUTICS CORPORATION | |||
| Dated: | January 26, 2004 | By: | /s/ Paul A. Mahon |
| Name: | Paul A. Mahon | ||
| Title: | EVP and General Counsel | ||
EXHIBIT INDEX
| Exhibit No. | Description of Exhibit | |
| 99 | Press Release dated January 26, 2004 |